Physician profile
Joe Hackworth
NPI 1619974987
$14,281.76
in general payments reported to CMS, 2019-2025
43 companies · $90.35 in 2025
The $90.35 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,528 · 2020: $1,638 · 2021: $2,366 · 2022: $2,456 · 2023: $3,449 · 2024: $754 · 2025: $90.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,087 · Travel and Lodging: $1,090 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,087.43 |
| Travel and Lodging | $1,089.84 |
| Education | $116.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $1,577.17 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $1,576.02 | 2019-2025 | |
| Amgen INC. | $1,479.19 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $1,167.49 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $941.31 | 2019-2024 | Farxiga, Wainua |
| Boston Scientific Corporation | $820.59 | 2019-2024 | Ekosonic, Bodyguardian |
| Abbott Laboratories | $774.98 | 2019-2023 | Coroflow |
| Boehringer Ingelheim Pharmaceuticals, INC. | $528.33 | 2019-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $524.05 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $378.92 | 2021-2023 | Verquvo |
| Amarin Pharma, INC. | $340.01 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $334.23 | 2019-2023 | Opsumit |
| Abiomed | $319.18 | 2019-2024 | Impella |
| Medtronic, INC. | $303.28 | 2022-2023 | Onyx Frontier |
| Daiichi Sankyo INC. | $290.14 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joe Hackworth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.